Evidence map›Paper›PMID 23962911›Full record

ReviewPharmacogenetics and genomics2013

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Christina L Aquilante, Mikko Niemi, Li Gong, Russ B Altman, Teri E Klein

Abstract readReview
In one paragraph

Review in Pharmacogenetics and genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Repurposing Drugs to Treat Heart and Brain Illness.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  12. Article
  13. Review
  14. Evaluation ofPharmacogenomics and personalized medicine · 2021
    Article
  15. Article
  16. Role of Genetic Variations in the Hepatic Handling of Drugs.International journal of molecular sciences · 2020 · on this map
    Review
  17. Article
  18. Article
  19. Review
  20. The influence ofBalkan journal of medical genetics : BJMG · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christina L AquilanteaDepartment of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado Departments of bGenetics cBioengineering, Stanford University, Palo Alto, California, USA dDepartment of Clinical Pharmacology, University of Helsinki, HUSLAB, Helsinki University Central Hospital, Helsinki, Finland.
Mikko Niemi
Li Gong
Russ B Altman
Teri E Klein

Funding

PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24GM61374
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Polymorphism, Single NucleotideAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAryl Hydrocarbon HydroxylasesBiotransformationChromosomes, Human, Pair 10Cytochrome P-450 CYP2C8Genetic VariationHaplotypesHumansHypoglycemic AgentsPharmacogeneticsAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAryl Hydrocarbon HydroxylasesCYP2C8 protein, humanCytochrome P-450 CYP2C8Hypoglycemic Agents

Identifiers

PMID23962911
PMCPMC4038626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.